Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
1. THRD announced Phase 1 trial results for THB335 in healthy volunteers. 2. THB335's reductions in serum tryptase support a Phase 2 trial planned for 2025. 3. Company halted non-THB335 research and reduced workforce by 50%. 4. Cash reserves expected to be $262M to $267M by June 2025. 5. CEO highlights strategic review for maximizing shareholder value.